相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
A critical role for Lyn in acute myeloid leukemia
Ceric Dos Santos et al.
BLOOD (2008)
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells
V. Papa et al.
LEUKEMIA (2008)
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
Jerome Tamburini et al.
BLOOD (2008)
A dual phosphoinositide-3-kinase α/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma
Qi-Wen Fan et al.
CANCER RESEARCH (2007)
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients
Jerome Tamburini et al.
BLOOD (2007)
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases
Florence I. Raynaud et al.
CANCER RESEARCH (2007)
Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling
Claire Chaussade et al.
BIOCHEMICAL JOURNAL (2007)
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts
P. L. Tazzari et al.
LEUKEMIA (2007)
A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16
C. Billottet et al.
ONCOGENE (2006)
A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling
Zachary A. Knight et al.
CELL (2006)
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Qi-Wen Fan et al.
CANCER CELL (2006)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia
A. M. Martelli et al.
LEUKEMIA (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
A pharmacological map of the PI3-K family defines a role for p110 alpha in insulin signaling
Zachary A. Knight et al.
CELL (2006)
mTOR regulates cell survival after etoposide treatment in primary AML cells
Q Xu et al.
BLOOD (2005)
Biology of normal and acute myeloid leukemia stem cells
JE Dick et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia
P Sujobert et al.
BLOOD (2005)
Antileukemic activity of rapamycin in acute myeloid leukemia
C Récher et al.
BLOOD (2005)
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold
ZA Knight et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2004)
Normal and leukemic hematopoiesis:: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?
E Passegué et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Survival of acute myeloid leukemia cells requires PI3 kinase activation
Q Xu et al.
BLOOD (2003)
Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable
YH Min et al.
LEUKEMIA (2003)
In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis
YE Claessens et al.
BLOOD (2002)
分享论文
